US tariff uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management called it 'hypothetical' and declined to provide specific mitigation strategy.
ALKEM / bear-case history
Track the concerns that keep returning.
Alkem Laboratories · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
US price erosion continues
US business faces 3-4% YoY price erosion, which could offset volume gains and pressure margins.
New business opex drag
CDMO and medtech businesses will incur significant opex (₹50-60 crore per quarter) in H2 FY26, delaying margin expansion.
Seasonality and incentive costs
Employee costs rose 15% YoY due to higher incentives; management expects lower growth in subsequent quarters, but volatility remains.
Price erosion in US generics
Sacubitril launch faces competitive pricing pressure; price erosion could impact US revenue growth in subsequent quarters.
GST impact on margins
GST revision will reduce benefits from Sikkim facility, causing a ₹50-60 crore impact in H2, pressuring margins.
US CDMO ramp-up and breakeven timeline
CDMO plant opex of ₹50 cr/quarter with only ₹20 cr revenue initially; breakeven expected in 12-18 months, but delays could weigh on profitability.
Penicillin G MIP uncertainty
Government may impose minimum import price on Penicillin G; management declined to comment, citing speculation, but it could increase costs.
Geopolitical supply chain disruptions
Rising logistics costs, API and packaging material prices due to geopolitical tensions could pressure margins.
US pricing erosion and competition
Base business in US faces value erosion; new launches may not fully offset if competition intensifies.
Trade generic growth slowdown
Trade generic business grew only ~4% due to restructuring; recovery may be slower than expected.
CEO transition uncertainty
CEO Dr. Vikas Gupta is leaving; new CEO search is ongoing, which could cause temporary strategic drift.